| |
|
<< Prev
18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 Next >> |
| |
Consultants Submit Draft AAV Guidance to FDA
[2703 Words]
[ Price : $8.95]
|
| Dark Horse Consulting Group submits a draft gene therapy guidance to FDA developed by former CBER staffer Donald Fink in consultation with other experts. |
|
05/17/2022
|
| |
|
| |
|
Improving Trial Representation Book
[2814 Words]
[ Price : $8.95]
|
| The National Academies produces a book on improving representation for women and minorities in clinical trials and research. |
|
05/17/2022
|
| |
|
| |
|
Apollo Care FDA-483
[2692 Words]
[ Price : $8.95]
|
| FDA releases the FDA-483 with five observations from an inspection at the Columbia, MO-based Apollo Care outsourcing facility. |
|
05/17/2022
|
| |
|
| |
|
Guide on Generic User Fee Assessments
[84 Words]
[ Price : $8.95]
|
| Federal Register notice: FDA makes available a final guidance entitled “Assessing User Fees Under the Generic Drug User Fee Amendments of 2017.” |
|
05/17/2022
|
| |
|
| |
|
Senate Bill to Restore FDA Orphan Drug Interpretation
[216 Words]
[ Price : $8.95]
|
| Senators Tammy Baldwin (D-WI) and Bill Cassidy (R-LA) introduce legislation entitled the Retaining Access and Restoring Exclusivity (RARE) Act, which addresses a 2021 court decision that adversely impacts how FDA interprets orphan drug exclusivity. |
|
05/17/2022
|
| |
|
| |
|
Senate Draft User Fee Bill Sets IVD Regulation
[401 Words]
[ Price : $8.95]
|
| The Senate HELP Committee releases a discussion draft of a bill that would reauthorize user fee programs for another five years and enhance certain other program areas, like the regulation of diagnostic tests and stronger oversight of cosmetics and dietary supplements. |
|
05/17/2022
|
| |
|
|
|
| |
|
FDA Hits Lupin’s Novel Labs with 13-item 483
[271 Words]
[ Price : $8.95]
|
| A March FDA inspection of Novel Laboratories (dba Lupin Somerset) leads to a 13-item FDA Form-483 that cites significant and repeat GMP deficiencies. |
|
05/16/2022
|
| |
|
| |
|
FDA Rejects EUA for Fluvoxamine in Covid
[246 Words]
[ Price : $8.95]
|
| FDA rejects an emergency use authorization request filed by University of Minnesota Medical School infectious disease physician David Boulware and other researchers to allow the use of generic drug fluvoxamine maleate for outpatient treatment of Covid-infected adults. |
|
05/16/2022
|
| |
|
|
|
| |
|
<< Prev
18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 Next >> |
| |
RSS
